Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt 0.78
MNKD's Cash to Debt is ranked higher than
54% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. MNKD: 0.78 )
MNKD' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.78

F-Score: 4
Z-Score: -7.79
M-Score: -5.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
ROA (%) -77.31
MNKD's ROA (%) is ranked higher than
57% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. MNKD: -77.31 )
MNKD' s 10-Year ROA (%) Range
Min: -393.74   Max: -52.52
Current: -77.31

-393.74
-52.52
ROC (Joel Greenblatt) (%) -108.34
MNKD's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. MNKD: -108.34 )
MNKD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -570.67   Max: -71.09
Current: -108.34

-570.67
-71.09
EBITDA Growth (%) -24.30
MNKD's EBITDA Growth (%) is ranked higher than
63% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. MNKD: -24.30 )
MNKD' s 10-Year EBITDA Growth (%) Range
Min: -43   Max: 10.9
Current: -24.3

-43
10.9
EPS Growth (%) -24.70
MNKD's EPS Growth (%) is ranked higher than
66% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. MNKD: -24.70 )
MNKD' s 10-Year EPS Growth (%) Range
Min: -42.9   Max: 7.6
Current: -24.7

-42.9
7.6
» MNKD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MNKD Guru Trades in Q4 2013

Murray Stahl 106,211 sh (+84.87%)
Steven Cohen 143,117 sh (-38.29%)
» More
Q1 2014

MNKD Guru Trades in Q1 2014

Murray Stahl 134,495 sh (+26.63%)
Steven Cohen 103,800 sh (-27.47%)
» More
Q2 2014

MNKD Guru Trades in Q2 2014

Jim Simons 1,769,800 sh (New)
Paul Tudor Jones 29,250 sh (New)
Murray Stahl 73,850 sh (-45.09%)
» More
Q3 2014

MNKD Guru Trades in Q3 2014

Murray Stahl 137,271 sh (+85.88%)
Jim Simons Sold Out
Paul Tudor Jones 11,246 sh (-61.55%)
» More
» Details

Insider Trades

Latest Guru Trades with MNKD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-03-31 Sold Out 0.01%$2.31 - $3.56 $ 5.4197%0
Jean-Marie Eveillard 2012-12-31 New Buy0.01%$1.85 - $2.83 $ 5.41150%800000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -11.44
MNKD's EV-to-EBIT is ranked higher than
65% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MNKD: -11.44 )
MNKD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -11.44

Current Ratio 0.66
MNKD's Current Ratio is ranked higher than
50% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. MNKD: 0.66 )
MNKD' s 10-Year Current Ratio Range
Min: 0.12   Max: 12.24
Current: 0.66

0.12
12.24
Quick Ratio 0.66
MNKD's Quick Ratio is ranked higher than
51% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. MNKD: 0.66 )
MNKD' s 10-Year Quick Ratio Range
Min: 0.12   Max: 12.24
Current: 0.66

0.12
12.24

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -8.70
MNKD's Earnings Yield (Greenblatt) is ranked higher than
69% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. MNKD: -8.70 )
MNKD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -9.3   Max: 0
Current: -8.7

-9.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NNF1.Germany,
MannKind Corp a development stage biopharmaceutical company, was incorporated in the state of Delaware on February 14, 1991. The Company is engaged in the discovery, development and commercialization of therapeutic products for diseases such as diabetes. Its product candidate, AFREZZA inhalation powder, is an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other product MKC253, MKC253 is a Technosphere formulation of GLP-1. Results from a phase 1 trial supported the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with type 2 diabetes. Products manufactured in the United States and marketed outside the United States are subject to certain FDA regulations, as well as regulation by the country in which the products are to be sold.
» More Articles for MNKD

Headlines

Articles On GuruFocus.com
What to Watch for: November 3-7 Nov 04 2014 
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune Aug 14 2014 
What This Upcoming Monday Means For MannKind Shareholders Aug 08 2014 
Shareholders To Inhale Relief As MannKind Found Its Bright Insulin Supply Partner Amphastar Aug 06 2014 
Shareholders To Inhale Relief As MannKind Found Its Bright Insulin Supply Partner Amphastar Aug 06 2014 
Osiris Stem Cells To Compliment Mannkind's Afrezza In Disrupting Diabetes Market Jul 29 2014 


More From Other Websites
MannKind Sees More Insider Selling Dec 04 2014
MannKind Corporation to Present at The 26th Annual Piper Jaffray Healthcare Conference Nov 25 2014
MannKind's Afrezza Remains in Sanofi's Plans, RBC Says Nov 21 2014
MANNKIND CORP Financials Nov 19 2014
10-Q for MannKind Corp. Nov 12 2014
MANNKIND CORP Files SEC form 10-Q, Quarterly Report Nov 10 2014
Diabetes Analyst: Sanofi CEO's Firing May Spell Trouble for MannKind Afrezza Partnership Nov 04 2014
[$$] MannKind's Progress Seen More Gradual Nov 04 2014
MannKind Falls on Missing Q3 Estimates Yet Cuts Loss Y/Y Nov 04 2014
Mannkind Corp Earnings Call scheduled for 5:00 pm ET today Nov 03 2014
MANNKIND CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 03 2014
MannKind Spending Trends See Improvements Nov 03 2014
MannKind Corporation Reports 2014 Third Quarter Financial Results Nov 03 2014
MannKind reports 3Q loss Nov 03 2014
MannKind reports 3Q loss Nov 03 2014
MannKind Corporation Reports 2014 Third Quarter Financial Results Nov 03 2014
Q3 2014 MannKind Earnings Release - Time Not Supplied Nov 03 2014
MannKind Corporation to Hold 2014 Third Quarter Financial Results Conference Call on November 3,... Oct 27 2014
MannKind Corporation to Hold 2014 Third Quarter Financial Results Conference Call on November 3,... Oct 27 2014
Goldman Sachs Analyst Neutral Rating of MannKind Feels Like Downgrade Oct 20 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK